View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
European Specialist in Veterinary Dentistry Lisa Milella has revealed in an interview with the Sunday People that she has been diagnosed with motor neurone disease, a condition which few people survive for more than 2-5 years.
It's hard to imagine anything much worse than being told in advance when your appointment with the Grim Reaper is booked, and for many the temptation might be just to give up there and then. Not Lisa. She embarked on the most extraordinary mission to fulfill ten of her life's ambitions.
The day after her diagnosis last August, she closed her veterinary practice in Byfleet. In December, she went sledging with huskies in Norway. In January, she flew to Borneo to carry out dental surgery on an orangutan. Three days later, she visited International Animal Rescue in Java and trained vets there to carry out dental work on slow lorises. She then celebrated her 40th birthday surrounded by friends and family in February. In May, she headed out to Peru to visit the Inca trail and the Amazon rainforest. From there, it was on to the Galapagos Islands. Then last week she went to India, where she trained another team to perform dental surgery on bears, and fulfil the 8th and 9th ambitions on her list, which were to operate on a leopard and a tiger.
Lisa closed her interview in the Sunday People saying: "I'm never going to get better and today is as strong as I'm ever going to be. You've got to make the most of now and not worry about tomorrow. Go out there and do it. You're never going to have that time again."
Oh. One other thing. Lisa's 10th wish was to get 100 strangers to donate £100 to International Animal Rescue. I hope you'll join me: https://www.justgiving.com/Lisa-Milella-100/
Ceva says the adverts, which will air on Channel 4 and Channel 4 partner channels until 20th January, will reach 15 million people. That might prove a conservative estimate though, because the Adaptil advert on YouTube has already had over 800,000 views, whilst the Feliway advertisement has had very nearly as many.
In addition, Adaptil has partnered with The Times to support its 'Walking the Dog' podcast series hosted by radio presenter and journalist Emily Dean.
During the podcasts, Emily talks with celebrities like Noel Fitzpatrick, Jimmy Carr, Rob Bryden and Jonathan Ross as they walk their dogs. An Adaptil advert airs at the start, middle and end of each podcast.
You can hear the podcasts on itunes here: https://itunes.apple.com/gb/podcast/walking-the-dog-with-emily-dean/id1220510307
Abigail King, behaviour product manager at Ceva Animal Health said: "Our new TV advertising campaigns and podcast partnership will boost awareness of both Adaptil and Feliway throughout the festive period and into January, when changes to routine, visitors in the household and loud noises from Christmas crackers and fireworks can challenge even the most laid-back pet."
For more information, visit: www.adaptil.com or www.feliway.com.
The plan is designed to help mimic the way cats eat in the wild and so provide them with both physical and mental stimulation. It also encourages cats to hunt, explore, climb and play – activities which boost cats’ positive behaviour and wellbeing.
Developed by feline behaviour specialist Dr. Sarah Ellis and Dr. Lizzie Rowe at International Cat Care, the plan is also designed to help to prevent overeating and promote a balance between energy intake and energy output, in order to avoid weight gain, as well as encouraging weight loss in overweight cats.
It is estimated that there are 10 million pet cats in the UK1 and the charity points to data which suggests that 39 – 52% of them are overweight or obese2,3, something which is a major health and welfare issue4-9, and can ultimately lead to early death10.
The charity says research shows that current feeding practices are contributing to this obesity epidemic, with a number of factors associated with a cat’s modern lifestyle leading to overeating. For example, most cats need little or no exertion to obtain their food, making it more likely that the calories they take in through eating will outweigh the calories they use up through exercise (leading to weight gain). Furthermore, the way we feed our cats generally does not match the lifestyle they were designed for, resulting in a lack of mental stimulation and reduced opportunity to express natural, instinctive hunting behaviours. This can lead to boredom, apathy, anxiety, frustration and stress in cats, resulting in reduced wellbeing and potentially the development of problem behaviours.
Sarah said: "By making a few simple changes to the way we feed our cats, we can help them to live longer, healthier and happier lives."
The plan recommends:
A detailed version of the feeding plan, along with the full report behind the development of the plan, can be found on International Cat Care’s website:
https://icatcare.org/advice/general-care/keeping-your-cat-healthy/feeding-your-cat-or-kitten
A short version of the feeding plan can also be found there.
References
Lead author Professor Clare Rusbridge, Chief of Neurology at Fitzpartick Referrals, conducted the study because of a lack of clarity on the recognition and diagnosis of the clinical signs associated with CM as opposed to syringomyelia (SM).
CM is an abnormality in the skull, making it smaller, and impacting on the brain to alter the flow of cerebrospinal fluid; this results in pain and a collection of fluid pockets within the spinal cord. These fluid pockets are commonly known as SM and over time can cause irreversible damage to a dog’s spinal cord. However it is not clear whether signs of pain in affected dogs are due to CM or SM or both.
To try to rectify this, Clare studied the medical records of all the cavalier King Charles spaniels diagnosed with CM-associated clinical signs presenting to her at Fitzpatrick Referrals over a five year period. She documented the historical and examination findings and related them to the MRI findings, including presence and size of the SM.
She found common signs in all dogs were vocalisation, spinal pain (neck, middle or lower back), reduced activity, reduced stairs or jumping ability, aversion to being touched or groomed, altered emotional state (described as being more timid, anxious, withdrawn or aggressive) and sleep disturbance.
A tendency to rub or scratch at the head or ears was common but was more likely in dogs with small or no SM suggesting that this may be a sign of head discomfort associated with CM. Head and ear rubbing was not associated with the presence of material within the middle ear (a condition which is also common in this breed and often given the acronym PSOM).
The only signs that were specific to SM were phantom scratching, scoliosis (twisted spine) and weakness and these were only present when the SM was large (at least 4mm wide).
Clare says this study is important because it suggests that CM alone is a cause of pain in many dogs. The aim now is to use the information gained in this study to develop a questionnaire to determine risk of CM and monitor the response to clinical signs.
Reference
Photo: Charlie on a bad day
Virbac has has announced the launch of Buprevet, a buprenorphine-based, injectable solution indicated for the potentiation of sedative effects of centrally-acting agents in dogs and for use in cats and dogs as part of a multimodal approach to analgesia.
Buprevet is presented in a 10 ml multi-dose bottle which can be broached up to 25 times and can be open for up to 28 days.
Sarah Walker MRCVS, Product Manager, said: "Buprenorphine is a potent, high affinity, synthetic opioid agonist which forms a key element of practice anaesthetic protocols and complements our existing anaesthetic range. Its potentiation effects means less sedation is needed in the pre-medication and in the anaesthesia, facilitating smoother recoveries with more comfortable patients."
"Buprenorphine is a tried and trusted solution for analgesia in many practices. Buprevet can be given pre-operatively to allow analgesia during and after surgery. It works effectively as part of a pre-emptive approach to analgesia, alongside products such as Inflacam and Carprox in our NSAIDs range."
Hot on the heels of Eurovet, Ceva Animal Health has launched Emeprid, containing the anti-emetic and pro-kinetic metoclopramide. Emeprid is licensed in cats and dogs for the symptomatic treatment of vomiting and reduced gastro-intestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs.
There are two formulations available; a 10ml multi-dose vial containing 5mg/ml metoclopramide for IV, SC or IM injection and a 125ml 'sweet orange and apricot flavoured' oral solution containing 1mg/ml metoclopramide. They are priced at £7.99 for the 10ml injectable bottle and £9.99 for the oral solution.
For further information, please contact your Ceva Animal Health representative or call the veterinary support team on 01494 781510.
Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
Baycox Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.
Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour at the University of Veterinary Medicine Hannover in Germany said: "Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen."
Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer said: "A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being.
"At the same time, farmers and workers can benefit from the reduced labour. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month."
For more information on Baycox Iron Injection, contact your local Bayer Animal Health representative.
Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.
Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.
The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.
The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G. Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.
Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect. A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.
There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.
Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"
Ms Evans was charged with causing or allowing a veterinary nurse colleague to order a prescription-only medicine from a practice supplier knowing that it was intended for human use, and made a false entry prescribing the medication on the clinical records of a cat belonging to her nurse colleague.
She was also charged with falsely recording details purporting to be the results of the blood tests on cat and then entering notes on the animal's clinical history which falsely indicated that there had been a meaningful result, and then indicating to the animal's owner that there had been a meaningful result, when in fact the tests had failed to produce any meaningful results.
The final charge was that her conduct in making the false entry for the prescription-only medication, and all elements of the second charge was dishonest and misleading.
Ms Evans admitted the first charge on the basis that she had allowed rather than caused the order to be made, all the other facts of this charge were admitted.
She admitted the second charge on the basis that she had failed to inform the cat’s owner of the test results, all the other facts of this charge were admitted.
She also admitted that elements of her conduct had been dishonest and misleading.
Having found the charges proven by Ms Evans’ admissions, the Committee considered whether her admitted actions and conduct amounted to serious professional misconduct.
Ms Evans, through her legal counsel, accepted that the admitted charges passed the threshold for serious professional misconduct, though that question still needed to be determined independently by the Committee.
The Committee found that Dr Evans’ conduct had breached several key parts of the Code of Professional Conduct and its supporting guidance, particularly around honesty and integrity.
It also found aggravating factors in this case, including the risk to human health by allowing the prescription-only medication to be ordered knowing it was for human use, the abuse of her professional position, the breach of client trust, the potential adverse impact on the welfare of the cat for whom she falsified the blood test records, and the potential adverse impact on the welfare of the cat for whom she had falsely recorded the prescription-only medicine.
The Committee found no mitigating factors relating to the facts.
Paul Morris, chairing the Committee and speaking on its behalf, said in relation to the first charge: “In the Committee’s view, this irresponsible approach to a prescription-only medicine risked human health, potentially compromised an animal’s welfare, since the clinical record suggested the cat had been given Fluconazole when it had not, constituted an abuse of the trust placed in her as a registered veterinary surgeon and was in breach of legal provisions designed to safeguard human health.
“Such behaviour falls far below the standard expected of a registered veterinary surgeon, undermines public confidence in the profession and would be considered deplorable by colleagues and the public alike.
"The Committee was thus satisfied that charge 1 on its own amounts to disgraceful conduct in a professional respect.”
He added: “Acting dishonestly runs contrary to one of the most fundamental principles of the profession.
"The public need to know that they can rely on the honesty and integrity of the people to whom they entrust the care and welfare of their animals.
“Further, Dr Evans’ conduct in both incidents had the potential to undermine public confidence in the profession of veterinary surgery and bring the profession into disrepute.
"In all the circumstances, the Committee was satisfied that Dr Evans’ behaviour as reflected in charge 2 fell far short of the standard expected of a veterinary surgeon and amounted to disgraceful conduct.
“Accordingly, the Committee found proved the allegation that Dr Evans was guilty of disgraceful conduct in a professional respect.”
Having found serious professional misconduct in relation to all charges, the Committee considered what the most appropriate and proportionate sanction would be for Ms Evans’ actions and conduct.
In doing so, it considered 137 positive references and testimonials from Dr Evans’ professional colleagues and clients, poor staff morale at the practice at the time as well as compelling, exceptional evidence relating to Dr Evans’s health at the time of the two incidents.
In mitigation, the Committee considered the fact that Dr Evans had no previous disciplinary history and had a hitherto unblemished career as a veterinary surgeon; her open and frank admissions; the circumstances of pressures at work exacerbated by Dr Evans’ desire to please everyone and not let anyone down; the fact that Dr Evans was feeling very isolated; the significant insight into her conduct and its impact; effective and targeted remediation to ensure there would be no likelihood of the conduct being repeated; genuine expressions or remorse and apology; support from her employers; and the very significant number of positive testimonials.
Summing up the Committee’s decision on sanction, Mr Morris said “In all the, somewhat exceptional, circumstances of this case, the Committee was satisfied that a reprimand and a warning not to behave in this way again, would provide adequate protection to animals, as it was satisfied Dr Evans was most unlikely to ever make such a flawed set of decisions again.
“The Committee was satisfied that Dr Evans does not represent a risk to animals going forward, indeed from the character evidence it is clear that she always puts the welfare of animals first.
"She has also shown, since this episode, that she can work under pressure and not resort to making bad decisions and thus the Committee considered the wider public interest would best be served in this case by a reprimand and a warning.
“Notwithstanding the serious nature of Dr Evans' conduct, the Committee was satisfied that a fully informed member of the public would not be shocked if Dr Evans were allowed to continue to practise.
“The decision of this Committee is, therefore, that Dr Evans be reprimanded and warned about her behaviour.
"Dr Evans should, however, be under no illusion of how serious it is to have a finding of disgraceful conduct in a professional respect made against her and she should not take lightly the decision of this Committee to reprimand and warn her.”
www.rcvs.org.uk/disciplinary
Jurox says Alfaxan Multidose is the bioequivalent to unpreserved Alfaxan, however the preserved formulation reduces the risk of microbial contamination, providing repeatable and reliable anaesthesia.
Alfaxan Multidose is available in two presentations of 10ml and 20ml, with the 20ml presentation priced at an equivalent price per ml as the current 10ml Alfaxan unpreserved presentation.
Jurox says there has been unprecedented interest in the new product, with the company taking pre-orders for the 20ml presentation from 60 different accounts at BSAVA this year.
Richard Beckwith, country manager at Jurox, said: "The introduction of Alfaxan Multidose to our anaesthesia and analgesia portfolio ensures that Alfaxan is more versatile than ever.
"The Alfaxan range continues to provide greater certainty and control during anaesthetic procedures, contributing towards better patient stability and a stress-free experience for the team."
For more information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
On 23rd March, the Government demanded that the majority of public-facing businesses close their doors. Veterinary surgeries, however, have been exempted and are allowed to remain open.
However, the number of clients seen face-to-face should be kept to an absolute minimum and veterinary teams must insist on strict social distancing measures at all times.
In addition, the RCVS/BVA say that:
The College has updated its FAQs for veterinary professionals, which can be found here: https://www.rcvs.org.uk/setting-standards/advice-and-guidance/coronavirus-covid-19/
The BVA is now developing some further guidance to provide examples of what constitutes routine, urgent and emergency care.
The Adaptil Diffuser has been renamed the Adaptil Calm Home Diffuser, the Adaptil Collar has been renamed Adaptil Calm On-the-Go Collar, Adaptil Spray is now called Adaptil Transport and Adaptil Tablets are now called Adaptil Express.
The new products are split into three colour-coded groups. In blue packaging, Adaptil Calm Home Diffuser is designed to help dogs stay calm in recurring situations at home, including staying alone, loud noises and visitors. It comes as a 30-day starter kit containing a diffuser and refill, and lasts for 30 days.
Adaptil Calm On-the-go Collar is for use when dogs face fearful situations outdoors. It is available in two collar sizes (small to fit necks up to 37.5cm and large to fit necks up to 62.5cm) and it lasts for four weeks.
Adaptil Transport comes in yellow packaging and is designed to make travel and visits to the vet less stressful. It is available in 60ml and 20ml bottles.
Adaptil Calm Home Diffuser, Adaptil Calm On-the-Go Collar and Adaptil Transport all contain dog appeasing pheremones to help dogs feel calm and relaxed.
The last product in the new range is Adaptil Express, which comes in green packaging. Adaptil Express is an oral supplement which Ceva says provides a fast, calming effect for dogs faced with occasional challenging events such as thunderstorms and fireworks. The non-pheromone tablets, which come in packs of 10 or 40 tablets, combine GABA and amino acids and can be given with or without food.
Abigail King, product manager for Adaptil, said: "80% of pet owners state that their dog gets stressed during challenging situations both inside and outside the home and during specific occasions such as travelling, fireworks and thunderstorms1. Adaptil’s new product range caters for all these eventualities and the eye-catching branding and packaging clearly indicates which product should be used for each challenging occasion to aid owner compliance and help dogs feel calm and relaxed at all times."
For further information, visit www.adaptil.com/uk.
Mr Roger faced three charges: that he had failed to provide adequate care, failed to communicate with the owner adequately and failed to keep adequate clinical records for Honey, a Shiih Tzu dog who, it transpired, had hypergycaemia.
At the initial consultation, Mr Roger took a blood sample which showed that there was an elevated blood glucose, an elevated white blood cell count, an elevated ALT and an elevated ALP (which Mr Roger took to be indicative of liver damage secondary to infection).
Mr Roger prescribed a cholagogue (ursodeoxycholic acid), an antibiotic (Synulox) and a diuretic (Frusemide).
In its findings of fact, the Committee found it likely that Mr Roger would have realised that Honey had a potential diabetes mellitus diagnosis with an elevated blood glucose of 28.
However, Mr Roger explained that he had believed the elevated blood glucose was due to the stress Honey had undergone in taking the blood samples.
The Committee therefore accepted that Mr Roger’s actions did not indicate a complete failure by him to notice the elevated blood glucose because he had explained he believed at the time it was due to stress.
Honey’s owner took her back to the veterinary practice that Mr Roger worked at three days later.
A different veterinary surgeon examined Honey and flagged that her blood sugar was high and that her liver was damaged.
She was taken to an alternative veterinary practice for follow-up but died later that day.
Mr Roger admitted failing to ask Honey’s owner if there was a history of diabetes mellitus, failing to take repeat blood glucose tests or carry out urine analysis or carry out additional blood tests, failing to communicate adequately with Honey’s owner about the significance of the hyperglycaemia and the options for investigation/management and failing to keep adequate clinical records in regard to Honey’s blood glucose levels.
The Committee found the admitted facts proved.
The evidence presented to the Committee included the clinical notes taken during Honey’s consultations, emails sent from Honey’s owner to the RCVS outlining the complaint, and evidence from experts in small animal veterinary practice.
Although the Committee found some matters not proved, it did find proved that Mr Roger had failed to recognise and/or pay adequate regard to Honey’s elevated blood glucose levels, had failed to manage Honey’s hyperglycaemia either by treating it or by documenting an appropriate plan to do so and had failed to communicate adequately with Honey’s owner about the significance of her elevated glucose and the reason for it.
Having reached its decision in relation to the facts, the Committee went on to consider whether the facts it had found proved either individually or cumulatively amounted to serious professional misconduct.
Judith Way, Chairing the Committee and speaking on its behalf said: “The Committee found that the charges and particulars it had found proved did not amount to disgraceful conduct in a professional respect either individually or cumulatively.
"In its judgment, the conduct found proved fell short of the standard to be expected of a reasonably competent veterinary surgeon but not far short of the standard which is expected of the reasonably competent veterinary surgeon.”
As a result of the Committee finding that Mr Roger was not guilty of serious professional misconduct on any of the proven charges, either individually or in any combination, the hearing did not proceed further.
The new rules will make it illegal to sell puppies younger than eight weeks and require anyone breeding and selling three or more litters of puppies a year to apply for a formal licence.
Those needing a licence, including online sellers, will also be required to display their permit in any advertising, and to give owners information about the five welfare needs that owners must meet under the Animal Welfare Act.
The penalty for breaking the new law will be an unlimited fine and/or up to six months in prison.
The plans also cover how pet shops, boarding houses and riding stables are licensed, introducing a single 'animal activities licence' to improve the process and make enforcement easier.
Environment Secretary Andrea Leadsom said: "Everyone who owns a pet or is looking to introduce one into their life will want to know that the animal has had the very best start to life. Yet for thousands of puppies born each year to irresponsible breeders, from smaller operations to larger puppy farms, their first weeks are spent in cramped and squalid conditions without the care and attention they need. That is why we are cracking down on the worst offenders by strengthening the dog breeding licence and giving councils the power they need to take action.
With more and more pet sales now taking place on the internet, it’s right that this market is subject to the same strict licensing criteria as other breeders and pet shops so that consumers are not misled. The plans announced today will help people choosing new family pets to be confident the animals have been properly bred and cared for from birth and are ready to move safely to their new homes.
Gudrun Ravetz, President of the British Veterinary Association, said: "This is a significant step in the right direction to improve the welfare of puppies and dogs in the UK, an issue our members are extremely concerned about as increasing numbers of poorly bred puppies are brought into veterinary practices.
"Poorly bred and badly socialised puppies cause terrible health and welfare problems for dogs so it is right that Defra has made irresponsible dog breeding a priority. We particularly welcome the move to make the sale of a puppy under eight weeks illegal, the reduction in the number of litters bred requiring a formal breeder’s licence, and the moves towards a single animal activities licence. In the future we would also like to see that anyone breeding from a dog should be required to register with their local authority.
"For these new measures to work in practice local authorities must have the necessary resources and support to fully enforce the legislation, supported by local veterinary expertise.
"We hope the new legislation will encourage owners to stop and think about where they’re getting their puppies from to tackle irresponsible breeding both at home and abroad. Prospective owners should do their homework and always use the puppy contract and information pack to make sure they ask breeders the right questions for a happy, healthy puppy."
The Kennel Club and Dogs Trust have welcomed the announcement.
Dogs Trust Veterinary Director, Paula Boyden said: "As the UK’s largest dog welfare charity, Dogs Trust welcomes the Government’s review of animal establishments licensing in England and the range of measures it sets out.
"We are particularly pleased that it will be illegal to sell a puppy below the age of 8 weeks and that there will be tighter licensing rules which will require sellers of pets to display their licence when advertising. We also applaud the move towards a risk based single licensing system which will incorporate those breeders that have gained UKAS approval rather than exempting them.
We believe that Local Authority Inspectors need support to enforce these tighter licensing rules. As such, moves to mandate the use of Model Conditions and for inspectors to be offered training and standards to be set is most welcome."
The referral centre recently extended its floor space at its base in Cheshire to support a major expansion of the services being offered, which include orthopaedic, soft tissue and spinal surgery and internal medicine; with specialist support in anaesthesia and pain management, a diabetes clinic, intensive care, cardiology, diagnostic imaging, neurology (medical and surgical) and oncology.
Liz Cousins, hospital manager at Northwest Veterinary Specialists, said: "The success of NWVS is down to the dedication of our highly skilled clinical, nursing and support teams.
"Our clinicians are well respected specialists in their chosen disciplines and it’s fantastic to be able to offer new services to pets and first opinion vets.
"The hospital is home to 88 colleagues and the change of name now reflects the growth and dedication by everyone here at Northwest Veterinary Specialists since opening in 2002."
Northwest Veterinary Specialists provides specialist veterinary services to veterinary practices in north west England and north and mid Wales.
Liz added: "At Northwest Veterinary Specialists we treat pets from as far apart as Carlisle, North Yorkshire and Staffordshire.
"The facilities are state-of-the-art, demonstrating a quality of service both for our clinicians and our clients, but most importantly the pets that we treat."
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.
Zenalpha provides restraint, sedation and analgesia during non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes2.
It is administered intramuscularly and takes effect within 5-15 minutes1, 2.
Dechra says patients also recover more rapidly2, potentially avoiding hospitalisation and allowing them to get home sooner.
Zenalpha contains the active ingredients 0.5 mg/ml medetomidine hydrochloride and 10mg/ml vatinoxan hydrochloride.
Medetomidine is an alpha-2 agonist used for its sedative and analgesic properties.
Vatinoxan is a peripherally selective alpha-2 antagonist which Dechra says has limited penetration across the blood-brain barrier, so it works to antagonise only the alpha-2 receptors located in the periphery, reducing cardiovascular side effects without impacting the quality of sedation or analgesia.
In a study of 223 dogs1 comparing a traditional alpha-2 agonist with Zenalpha, Zenalpha was found to minimise cardiovascular side effects while preserving reliable sedation and analgesia.
Claire Westoby, brand manager at Dechra said: ‘The next generation of alpha-2 agonists have evolved to provide the same effective and reliable sedation and analgesia, but with reduced cardiovascular side effects and a reduced chance of vomiting.
"This improves the sedation experience for the canine patient, as well as reducing the associated stress commonly experienced by veterinary teams and dog owners.”
Matt Gurney FRCVS, an RCVS and EBVS European Specialist in Veterinary Anaesthesia and hospital director at Anderson Moores, said: “It is really exciting to see the launch of an innovative new product, especially one with a unique mechanism of action that will improve the sedation experience for the vet team and our patients.
"Zenalpha not only provides a solution to cases where IV placement is not possible and a rapid onset IM option is required, but it also offers a rapid and complete recovery which ensures that dogs can be reunited with their owners and return home as soon as possible.”
Zenalpha is presented in a 10 ml glass vial in individually packed cardboard boxes.
For more information: www.dechra.co.uk/zenalpha or contact your local Dechra territory manager.
To watch Matt Gurney’s ‘Zennovation in sedation – the next generation of alpha-2 agonists’: www.dechra.co.uk/academy.
Sam and Dick will be joint Clinical Directors of the hospital and co-owners of the business alongside the Pets at Home Vet Group, their Shared Venture Partner.
They say the vision is to create a world-class facility with a team of highly motivated veterinary specialists, nurses and support colleagues providing outstanding levels of service to meet the needs of referring veterinary surgeons, their clients and patients.
The purpose-built facility will offer specialist referral services across a range of disciplines, including anaesthesia, diagnostic imaging, internal medicine, orthopaedics, neurology and soft tissue surgery. Emergency referrals will be accepted seven days a week, 24 hours a day.
Sam said: "It is truly exciting to build a new team of experienced specialists who have clinical excellence as their priority. We also relish the chance to develop great relationships with professional colleagues in first opinion practices. This will allow our hospital to deliver an exceptional level of service for referring veterinary surgeons and their patients."
Dick said: “This is a very exciting step and I am delighted to be instrumental in ensuring that our new centre in Scotland offers the very best in veterinary care”.
The hospital will be based at Deer Park in Livingston, with convenient parking and easy access to the M8 and other major road and rail networks. In addition to clinical services, it will provide a CPD programme, including internship and residency opportunities.
The new product is being sold through e-retailers including Pet Drugs Online, Animed and Pets at Home.
Frontpro is claimed to kill fleas within 8 hours and protect dogs from fleas and ticks for one month.
It is suitable for all breeds aged eight weeks or older (weighing two kilograms or more) and can be given with or without food.
A company spokesperson said: "Boehringer Ingelheim is committed to expanding access to high-quality parasite prevention for dogs, which is why we’re proud to introduce an effective new option.
"Frontpro chewable tablets provide effective protection from fleas and ticks, while complementing the regular care and advice pet owners receive from their veterinarians."
www.uk.frontline.com
In case you missed the email last month, Novartis Animal Health has announced the launch of Atopica for Cats (cyclosporine oral solution, 100 mg/ml), a treatment for chronic allergic dermatitis.
This disease, which is apparently one of the most common reasons for pet owners to take cats to the veterinary surgeon2, can be difficult to diagnose and causes itching and associated chewing and licking, skin lesions and loss of hair. Atopica for Cats is the first medication approved in the UK specifically for allergic dermatitis in cats.
Novartis says the new product provides relief from the uncomfortable and recurrent itch/scratch cycle, and the majority of improvements are seen in the first four weeks3-5. The company also says that in clinical trials, 84 per cent of cats diagnosed with allergic dermatitis were considered to be "uncomfortable" at the start of the study5. After six weeks of treatment with Atopica for Cats, 78 per cent of cats were considered "comfortable" with satisfactory levels of grooming3 - a key indicator of a healthy cat. Additionally, Atopica for Cats is proven to significantly reduce unsightly and painful skin lesions and has a proven safety profile.
Anne-Laure Driscoll, Atopica Brand Manager, Novartis Animal Health UK, said: "Veterinarians and pet owners understand the discomfort and frustration of an itchy pet. We are pleased to add Atopica for Cats to our proven family of Atopica products, offering an effective treatment for cats suffering from the extreme discomfort associated with allergic dermatitis."
Developed specifically for domestic felines, Atopica for Cats is an oral solution which Novartis says is easy-to-dose and administer. In studies, approximately one-third of cats took the medicine in their food and two-thirds were dosed directly into the mouth3,4. According to the company, the product offers a unique mode of action that specifically targets immune cells such as the T-lymphocytes involved in the allergic reaction. In this way, Atopica for Cats blocks the production of inflammatory cytokines, molecules that fuel the allergic response, breaking the recurrent itch/scratch cycle.
Dr. Keith Hnilica, DVM, MS, MBA and DACVD, and author of Small Animal Dermatology: A Color Atlas and Therapeutic Guide (3rd ed), said: "Atopica for Cats has the potential to change how our profession treats the itchy cat. For the first time ever, we have a safe, highly effective, approved treatment for cats with allergic dermatitis. And because Atopica for Cats is not a corticosteroid, I can prescribe it for long-term use without worrying about the health risks that can be associated with steroids."
David, who was assisted by Dan Kenny and Kat Grzywa MsRCVS, said: “Penny presented with suspected ascites, given a large volume of peritoneal effusion. Her abdomen was very swollen and taut
“We performed a contrast-enhanced CT scan with an iodine-based contrast to help highlight the areas of the body we needed to examine and the results were startling.
“The mass was enormous. It almost completely filled the abdomen.”
CT images showed that the mass had originated in the right kidney, which had been displaced into the left side of the abdomen, and also compressed the rest of Penny’s internal organs.
There was no evidence of metastatic disease.
David added: “A right ureteronephrectomy was performed and the large cystic parts of the tumour were dissected free from the omentum, the peritoneum and the retroperitoneal vasculature.
“The surgery was really difficult because the mass was so large and heavy, and it required extra surgeons to hold and manipulate the mass, while its vasculature was dissected and ligated.
“The weight of the mass on the diaphragm also made the anaesthesia challenging but surgery went very well.
"Once the surgery was over, the weight of the mass was confirmed at nearly 5kg.
“Penny made a good recovery from the anaesthesia, her blood renal parameters remained normal throughout her recovery, and she was discharged 48 hours later. Histopathology later confirmed the mass to be renal carcinoma.”
Virbac Animal Health has announced that its medical castration implant Suprelorin 9.4mg has received a marketing authorisation for use in ferrets.
The neutering of male ferrets (hobs) is recommended to suppress fertility, decrease odour and reduce territorial aggressive behaviour and urinary marking¹. According to Virbac, Suprelorin offers temporary sterilisation but without the need for surgery, and its use prevents the high Luteinizing hormone (LH)/Follicle-stimulating hormone (FSH) levels which occur following surgery and which can play a role in the development of hyperadrenocorticism².
Suprelorin is a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin. Once injected under the skin of healthy, sexually mature and entire ferrets, the continuous low release of deslorelin from the implant causes an interruption of the HPA circuit, leading to a reduction in LH/ FSH levels and therefore testosterone production. This results in a reduction of libido, spermatogenesis and testicle size.
The implant lasts for up to four years, at which stage the ferret can be re-implanted to maintain the effect.
Chris Geddes MRCVS, Virbac Product Manager, said: "For owners looking for a surgery-free route to the castration of male ferrets and the problems it can cause, Suprelorin provides a simple and effective alternative."
Suprelorin 4.7mg has been available for use in dogs since 2008. Suprelorin 9.4mg was launched in 2011.
For further information, please contact your Territory Manager or call Head Office on 01359 243243.
References:
The research, conducted with the Blue Cross, analysed data from over 2,000 UK dog owners and identified perceptual barriers to welfare reforms.
The study revealed that many owners normalise health issues associated with brachycephalic conformations, including breathing difficulties, eye conditions, and skin infections.
One in seven owners of extreme brachycephalic dogs said that 'nothing' could dissuade them from owning these breeds, particularly those with a strong preference for flat faces and those that did not believe brachycephaly reduced a dog’s lifespan.
Owners of extreme brachycephalic dogs, such as French Bulldogs, found the perceived trait of 'laziness' to be highly desirable, despite the fact that an inability to exercise is often a symptom of brachycephalic obstructive airway syndrome (BOAS).
The researchers propose a series of interventions to overcome these barriers and make campaigning more effective, including:
Dr. Rowena Packer, lead researcher, said: "Future strategies to tackle the brachycephalic crisis must do more than presenting purely health-based data in generic public locations, and instead, positively offering possible alternate breeds, myth-busting false beliefs and leveraging human stories of brachycephalic owners to have greater impact.
"Additionally, specifically targeting these messages on social media and puppy-selling platforms may increase their efficacy.”
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk